Novartis will continue to be on the lookout for bolt-on deals below $2 billion, CEO Vas Narasimhan said Tuesday on the pharma ...

Axiom Biosciences is thinking outside of the box, betting on a public debut in Hong Kong to raise capital and grow into a ...

Eighteen companies have gone public this year so far, putting 2026 on pace to record the highest number of IPOs since the ...

Roche has 19 investigational medicines that could launch by 2030—and even if not all of them make it to market, the company is “well set-up for growth into the next decade,” CEO Thomas Schinecker said ...

The Phase 3 results are the first direct proof-of-concept for an ADC replacing platinum-based chemo in a first-line ...

After committing $55 billion last year to bolster U.S. manufacturing capabilities, Johnson & Johnson is making changes to its ...

New mid-stage data from Biogen’s Ionis-partnered therapy diranersen served to both validate the tau hypothesis in Alzheimer’s ...

Biopharma companies won’t fully capture the benefits of AI unless they reorganize their R&D units, according to McKinsey.

Eli Lilly’s anti-amyloid Alzheimer’s drug is designed to be stopped after patients drop below a certain amyloid level in the ...

An unnamed pharma filed a citizen petition in April seeking reforms to the way the FDA publicly releases rejection letters, ...

Top-selling cell therapies from BMS, J&J and Gilead depend on a BioLife product, positioning Repligen to use the takeover to increase its exposure to the modality. Repligen has inked a $1.5 billion ...

The discontinued asset, being trialed for breast cancer and solid tumors, had yielded disappointing data, leading to Novartis’ decision to abandon development, according to a company spokesperson.